A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc.
A2 Biotherapeutics Inc.
National Institutes of Health Clinical Center (CC)
Novartis
Nurix Therapeutics, Inc.
Context Therapeutics Inc.
NuCana plc
PharmaMar
Aalborg University Hospital
Azienda USL Reggio Emilia - IRCCS
Cancer Research UK
Novartis
Checkpoint Therapeutics, Inc.
Aminex Therapeutics, Inc.
University of California, San Diego
Oslo University Hospital
Capital Medical University
Multitude Therapeutics Inc.
Duke University
Quadriga Biosciences, Inc.
AbbVie
AbbVie
Aduro Biotech, Inc.
Abramson Cancer Center at Penn Medicine
Novartis
GlaxoSmithKline
Bayer
Oshadi Drug Administration
University Hospital, Ghent
Abramson Cancer Center at Penn Medicine
Valerio Therapeutics
Children's Oncology Group
INSYS Therapeutics Inc
University of Chicago
GlaxoSmithKline
National Institutes of Health Clinical Center (CC)
Astellas Pharma Inc
National Cancer Institute (NCI)
Pfizer
Anza Therapeutics, Inc.